Time-in-range derived from self-measured blood glucose in people with type 2 diabetes advancing to iGlarLixi: A participant-level pooled analysis of three phase 3 LixiLan randomized controlled trials.
從自我測量血糖得出的時間範圍在進入 iGlarLixi 的 2 型糖尿病患者中的應用：三項第 3 期 LixiLan 隨機對照試驗的參與者層級匯總分析。
Diabetes Obes Metab 2024-09-08
Higher Derived Time in Range With IDegLira Versus Insulin Glargine U100 in People With Type 2 Diabetes.
IDegLira 在 2 型糖尿病患者中比 Insulin Glargine U100 有更高的血糖範圍衍生時間。
J Diabetes Sci Technol 2024-05-15
Effectiveness and Safety of iGlarLixi (Insulin Glargine 100 U/mL Plus Lixisenatide) in Type 2 Diabetes According to the Timing of Daily Administration: Data from the REALI Pooled Analysis.
iGlarLixi（胰島素格拉凝100 U/mL 加 利西那酯）在第2型糖尿病患者中根據每日給藥時間的有效性和安全性：來自REALI合併分析的數據。
Diabetes Ther 2023-04-03
iGlarLixi (insulin glargine 100 U/ml plus lixisenatide) is effective and well tolerated in people with uncontrolled type 2 diabetes regardless of age: A REALI pooled analysis of prospective real-world data.
iGlarLixi（胰島素格拉凝100 U/ml 加 利西塞肽）對於控制不佳的 2 型糖尿病患者具有效性且耐受性良好，年齡無關：REALI 前瞻性實務數據的綜合分析。
Diabetes Obes Metab 2023-05-13
iGlarLixi provides a higher derived time-in-range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis.
iGlarLixi在亞太地區2型糖尿病患者中提供比較胰島素glargine 100 U/mL或lixisenatide更高的時間範圍：事後分析。
Diabetes Obes Metab 2023-06-06
Clinical Benefits of Treating Patients with Type 2 Diabetes Mellitus with iGlarLixi: A Patient-Level Simulation Study.
使用 iGlarLixi 治療 2 型糖尿病患者的臨床益處：一項患者層級模擬研究。
Diabetes Ther 2023-08-01
Advancing type 2 diabetes therapy with iGlarLixi in older people: Pooled analysis of four randomized controlled trials.
在老年人中透過 iGlarLixi 推進第二型糖尿病治療：四項隨機對照試驗的綜合分析。
Diabetes Obes Metab 2024-02-06
Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan-O-AP and LixiLan-L-CN trials.
年齡和疾病持續時間對亞洲2型糖尿病患者使用 iGlarLixi 的療效和安全性的影響：LixiLan-O-AP 和 LixiLan-L-CN 試驗的事後分析。
Diabetes Obes Metab 2024-04-07
Comparison of efficacy and safety of insulin degludec/liraglutide and insulin glargine U-100/lixisenatide in individuals with type 2 diabetes mellitus using professional continuous glucose monitoring.
胰島素 degludec/liraglutide 與胰島素 glargine U-100/lixisenatide 在使用專業連續葡萄糖監測的 2 型糖尿病患者中的療效和安全性比較。
J Diabetes Investig 2024-05-02
Real-world effectiveness of GLP-1 receptor agonist-based treatment strategies on "time in range" in patients with type 2 diabetes.
GLP-1 受體激動劑治療策略對第二型糖尿病患者「範圍內時間」的實際效果。
Front Pharmacol 2024-03-23
Real-Life Effectiveness of iGlarLixi (Insulin Glargine 100 U/ml and Lixisenatide) in People with Type 2 Diabetes (T2D) According to Baseline HbA1c and BMI.
iGlarLixi（Insulin Glargine 100 U/ml 和 Lixisenatide）在2型糖尿病（T2D）患者中根據基線 HbA1c 和 BMI 的實際效果。
Diabetes Ther 2024-09-14